Development of APE1 Inhibitors for Melanoma and Glioma
Author Information
Author(s): Mohammed M Z, Vyjayanti V N, Laughton C A, Dekker L V, Fischer P M, Wilson D M III, Abbotts R, Shah S, Patel P M, Hickson I D, Madhusudan S
Primary Institution: University of Nottingham
Hypothesis
Can small molecule inhibitors of APE1 enhance the response to chemotherapy in melanoma and glioma?
Conclusion
The study provides evidence that APE1 is a promising drug target and its inhibitors could improve treatment outcomes in melanoma and glioma.
Supporting Evidence
- Several specific APE1 inhibitors were isolated with IC50 values ranging from 30 nM to 50 μM.
- APE1 inhibitors led to the accumulation of AP sites in genomic DNA.
- These inhibitors potentiated the cytotoxicity of alkylating agents in melanoma and glioma cell lines.
Takeaway
Scientists are trying to make new medicines that can help treat skin and brain cancers by blocking a protein called APE1 that helps cancer cells survive.
Methodology
The study used high throughput virtual screening and in vitro assays to identify and evaluate APE1 inhibitors.
Limitations
The study primarily focuses on in vitro results, and further in vivo studies are needed to confirm the efficacy of the inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website